Detalhe da pesquisa
1.
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial.
Br J Haematol
; 201(2): 267-279, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36541152
2.
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Eur J Haematol
; 108(1): 73-83, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34496096
3.
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
PLoS Med
; 18(1): e1003454, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33428632
4.
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
Br J Haematol
; 192(5): 853-868, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32656799
5.
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
Haematologica
; 106(7): 1957-1967, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32499244
6.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 20(6): 781-794, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31097405
7.
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 20(1): 57-73, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30559051
8.
Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial.
Leukemia
; 35(7): 2043-2053, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33262523
9.
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Lancet Haematol
; 6(12): e616-e629, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31624047
10.
Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.
Blood Cancer J
; 12(11): 162, 2022 11 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36446771
11.
Replacing urine protein electrophoresis with serum free light chain analysis as a first-line test for detecting plasma cell disorders offers increased diagnostic accuracy and potential health benefit to patients.
Am J Clin Pathol
; 140(6): 890-7, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24225758
12.
Autoimmune neutropenia following therapy for chronic lymphocytic leukaemia: a report of three cases.
Br J Haematol
; 136(2): 348-9, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17156393